Navigation Links
Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
Date:5/13/2009

NERVIANO, Italy, May 13 /PRNewswire/ -- The FDA has approved an Investigational New Drug (IND) application by Nerviano Medical Sciences to begin a phase I clinical study with its selective PLK-1 small molecule inhibitor for the treatment of cancer. PLK-1 is a mitotic kinase required for the proliferation of cancer cells. This new compound is orally bioavailable, highly efficient and well tolerated in preclinical models of cancer after repeated dosing. This unique inhibitor adds another promising candidate to the pipeline of innovative cell cycle targets with different mechanisms of action in clinical development which have been discovered and developed by NMS. These include inhibitors of CDK, Aurora and CDC-7. An IND for an inhibitor of CDC-7 was approved by the FDA in January this year and the first patients were treated with the compound in April. NMS CDK and Aurora inhibitors are in phase I and II clinical development, respectively, and are starting to show promising activity in specific patient populations.

The clinical development path foresees application of the NMS PLK-1 inhibitor in solid and hematological indications. "I am pleased to see the second IND approval this year and I highly appreciate the consistant delivery of high quality clinical candidates by the Nerviano site" comments Dr. Francesco Colotta, VP R&D at NMS.

Nerviano Medical Sciences (NMS)

Nerviano Medical Sciences is the largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe. Research activities in Nerviano generate on average two clinical candidate molecules per year. NMS takes advantage of strategic alliances with biotechnology as well as pharmaceutical companies to secure its long term business sustainability. The Company has already finalized partnerships with major companies such as Pfizer Inc., Bristol-Myers Squibb Co., Genentech Inc. as well as with several biotech companies and academic institutions.

    For information:

    Nerviano Medical Sciences
    Maria D'Acquino,
    tel +39-0331-581013,
    mob. +39-335-1863051,
    maria.dacquino@nervianoms.com



'/>"/>
SOURCE Nerviano Medical Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical Announces First quarter 2009 results
2. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
3. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
4. Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition
5. ATS Medical Announces Participation in the Annual Meeting of the American Association for Thoracic Surgeons
6. University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System
7. Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury
8. Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff
9. Nfocus Neuromedical Appoints Robert OHolla to Head Regulatory
10. Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing
11. BioMS Medical to present at Alberta Economic Forum in Geneva
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016  The Multiple Myeloma Research Foundation (MMRF) today ... Study SM —the largest and most comprehensive study driving ... myeloma—will be presented at the 58 th American ... San Diego from December 3-6. ... as well as identify pathways and targets for new ...
(Date:12/2/2016)... ... 2016 , ... ACEA Biosciences, Inc. announced today that it will be presenting ... the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 01, 2016 , ... ... event is expanding to three days and will take place on February 1-3, 2017 ... (GSK) and Dr James Gulley (NCI), the program provides a unique 360-degree approach, which ...
(Date:12/2/2016)... MA (PRWEB) , ... December 02, 2016 , ... Robots ... Light Event on December 3rd, 2016. The event, which is held on the ... work with helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering ...
Breaking Biology Technology:
(Date:11/17/2016)... INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has just ... servers in organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
Breaking Biology News(10 mins):